Amygdala Neurosciences

Newleos Therapeutics

The company develops oral small-molecule drugs to treat neuropsychiatric disorders, including anxiety and substance use disorders, for patients seeking therapies with fewer side effects.

Sobrera Pharma

This pharmaceutical company develops medical treatments for patients suffering from alcohol use disorder and other addiction-related conditions.

Engrail

This clinical-stage pharmaceutical company develops targeted small-molecule medicines for patients with neuropsychiatric and neurodevelopmental disorders.

Enabling psychedelics-assisted therapies

This biopharmaceutical company develops psychedelic-inspired medicines and a care delivery model to treat addiction for patients and healthcare providers.

Opiant

This company develops pharmacological treatments for substance use, addictive and eating disorders for patients and healthcare providers.

Pleo Pharma

This pharmaceutical company develops oral treatments to mitigate cannabis withdrawal symptoms for adult patients with cannabis use disorder.

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.

LB Pharmaceuticals

This company develops oral small-molecule antipsychotic therapies for patients with schizophrenia, bipolar depression, and other neuropsychiatric disorders.